5 December 2016 · This document is aimed at staff in UK NHS hospitals considering or already sourcing their supply of chemotherapy as ready-to-administer doses.
16 December 2016 · The purpose of this document is to give guidance to those outsourcing PN compounding on the risks in the outsourcing and supply process and to…
10 October 2019 · A joint statement from the Neonatal and Paediatric Pharmacy Group (NPPG) and the Royal College of Paediatrics and Child Health (RCPCH)
8 January 2020 · A legal position summary regarding the sale, supply or administration of off-label/unlicensed products under Schedule 17 of the Human Medicines Regulations 2012
4 June 2021 · The stability of several aseptically compounded ready to administer presentations of monoclonal antibody products and other biopharmaceuticals is presented.
1 March 2022 · National guidance from NHSE/I to reduce LASA errors and improve patient safety when considering requirements for unlicensed specials medicines